Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ashok Ettam maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active for this entity. This prosecution is managed by a distinct examiner, which reflects a focus for the portfolio's current legal activity at the patent office. Such a concentrated profile often indicates a core technology or an early stage of portfolio development.
The portfolio's examination is occurring within 1 distinct art unit. JOHN S KENYON is the busiest examiner associated with the portfolio, holding a pending office action. This examiner's workload represents the total pending office actions for the company, showing that the current prosecution efforts are concentrated under an individual's review within the biotechnology sector. For the applicant, this means that the prosecution strategy is dependent on the interactions with this specific examiner and the standards of a particular art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702429 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702429 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | KENYON, JOHN S | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702429 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | KENYON, JOHN S | 1629 | §102§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAshok Ettam has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John S Kenyon has the most, with 1 of Ashok Ettam's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
